Digital Trial Solutions

Digital Trial Solutions (DTS) is a comprehensive digital platform designed to revolutionize clinical trial operations by integrating real-world data, site-level insights, and advanced automation. It supports every phase of clinical trials, from protocol design and site selection to patient matching and workflow automation, aiming to reduce site burden, enhance enrollment speed, and improve data quality.

Powered by agentic AI and top-tier real-world data, DTS facilitates smarter, faster, and more inclusive oncology trials. The platform offers several key benefits:

• Efficiency: Automates screening and data workflows to reduce site burden and accelerate time-to-enrollment.
• Precision: Utilizes eligibility likelihood scores and predictive progression modules to match the right patients to the right trials.
• Speed: Features real-time feasibility dashboards and site-specific enrollment forecasting to expedite trial startup.
• Inclusion: Expands trial access through low-burden options and community site enablement, enhancing patient diversity.

DTS's core capabilities include:

Study Design & Optimization

Leverages real-world data to test inclusion/exclusion criteria against live oncology datasets, identify diversity and enrollment barriers early, model trial-ready patient cohorts, and refine protocols to speed up recruitment.

Site Feasibility & Selection

Evaluates site performance by indication and demographic, uses patient forecasts to target diverse and capable centers, integrates with national networks like CancerLinQ and Exigent Research Network, and monitors projected enrollment timelines in real time.

Patient Matching

Employs AI-powered, real-time pre-screening to continuously screen patients with every data refresh, match candidates based on clinical, molecular, and social determinants of health data, reduce coordinator time with ranked candidate lists, and improve trial diversity through inclusive cohort identification.

ConcertAI's DTS is recognized for fundamentally changing clinical research processes, from study design to execution, and is anticipated to become a gold standard for oncology studies. The platform's innovative approach has been demonstrated through successful collaborations, such as with Bristol Myers Squibb, to accelerate access to innovative cancer treatments.